文献速递青光眼神经眼科

初始视盘毛细血管密度丢失速率与视野进展风险

Rate of Initial Optic Nerve Head Capillary Density Loss and Risk of Visual Field Progression.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

这项回顾性纵向队列研究纳入167只眼(96只原发性开角型青光眼、71只青光眼疑似),随访平均5.7年,评估初始视盘OCTA毛细血管密度丢失速率与视野进展的关联。快速OCTA进展眼视野进展风险约为非快速进展眼的1.96倍,且视野丢失速率更快。

要点

  • 快速OCTA进展眼视野进展风险约为非快速进展眼的1.96倍(HR 1.96,95%CI 1.04-3.69,P=0.04)。
  • 快速OCTA进展眼视野丢失速率较慢速进展眼每年多-0.18 dB(95%CI -0.30至-0.06,P=0.004)。
  • 快速OCT进展眼视野丢失速率较慢速进展眼每年多-0.17 dB(95%CI -0.29至-0.06,P=0.002)。

核心结论

  • 初始视盘OCTA毛细血管密度快速丢失与更快的视野进展速率相关,并使事件进展风险约翻倍。

研究设计与样本

  • 回顾性纵向队列研究,纳入青光眼转诊中心167只眼(96只原发性开角型青光眼、71只青光眼疑似)共109例患者,平均随访5.7年(2015年1月至2022年12月),数据分析于2023年4月进行。

主要发现

  • 快速OCTA进展眼84只、慢速83只,初始毛细血管密度丢失速率分别为每年-1.17%和-0.45%(平均差-0.72%/年,95%CI -0.84至-0.60,P<0.001)。
  • 快速OCT进展眼84只、慢速83只,初始视网膜神经纤维层变薄速率分别为每年-0.60 μm和-0.09 μm(平均差-0.51 μm/年,95%CI -0.59至-0.43,P<0.001)。
  • 快速OCTA进展眼视野丢失速率较慢速进展眼每年多-0.18 dB(95%CI -0.30至-0.06,P=0.004);快速OCT进展眼每年多-0.17 dB(95%CI -0.29至-0.06,P=0.002)。
  • 快速OCTA进展眼发生视野进展的风险约为非快速进展眼的1.96倍(HR 1.96,95%CI 1.04-3.69,P=0.04)。
  • 52只同时快速OCTA和OCT进展眼中17只(32.7%;95%CI 32.5-32.8)随后发生可能的视野进展。

临床怎么用

  • 作者认为这些发现可能支持临床使用OCTA和OCT视盘测量进行青光眼进展风险评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Rapid initial optic nerve head capillary density loss may be used to assess the risk of glaucoma visual field progression. OBJECTIVE: To investigate the association between the rate of initial optic nerve head capillary density loss from optical coherence tomography angiography (OCTA) and visual field progression. DESIGN, SETTING, PARTICIPANTS: This was a retrospective study of a longitudinal cohort at a glaucoma referral center. A total of 167 eyes (96 with primary open-angle glaucoma and 71 with glaucoma suspect) of 109 patients were monitored for a mean (SD) of 5.7 (1.4) years from January 2015 to December 2022. Data analysis was undertaken in April 2023. MAIN OUTCOMES AND MEASURES: The rates of initial capillary density and average retinal nerve fiber layer loss were calculated from the first 3 optic nerve head OCTA and OCT scans, respectively, during the initial follow-up (mean [SD], 2.0 [1.0] years). Based on the median rate, eyes were categorized into fast and slow progressor groups. The association between initial capillary density change or retinal nerve fiber layer thinning and visual field progression was evaluated using linear-mixed and time-varying Cox models. RESULTS: A total of 167 eyes of 109 patients (mean [SD] age, 69.0 [11.1] years; 56 [51.4%] female and 53 [48.6%] male) were assessed. Eighty-three eyes were slow OCTA progressors, while 84 eyes were fast with mean capillary density loss of -0.45% per year and -1.17% per year, respectively (mean difference, -0.72%/year; 95% CI,-0.84 to -0.60; P < .001). Similarly, 83 eyes were slow OCT progressors, while 84 eyes were fast with mean retinal nerve fiber layer thinning of -0.09 μm per year and -0.60 μm per year, respectively (mean difference, -0.51 μm/year; 95% CI,-0.59 to -0.43; P < .001). The fast OCTA and OCT progressors were associated with more rapid visual field loss (mean difference, -0.18 dB/year; 95% CI,-0.30 to -0.06; P = .004 and -0.17 dB/year; 95% CI,-0.29 to -0.06; P = .002, respectively). Fast OCTA progressing eyes were more likely to have visual field progression (hazard ratio, 1.96; 95% CI, 1.04-3.69; P = .04). Seventeen of 52 eyes (32.7%; 95% CI, 32.5-32.8) with fast OCTA and OCT progression developed subsequent visual field likely progression. CONCLUSION AND RELEVANCE: Rapid initial optic nerve head capillary density loss from OCTA was associated with a faster rate of visual field progression and a doubling of the risk of developing event progression in this study. These findings may support clinical use of OCTA and OCT optic nerve head measurements for risk assessment of glaucoma progression.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tansuebchueasai N, Nishida T, Moghimi S, et al. Rate of Initial Optic Nerve Head Capillary Density Loss and Risk of Visual Field Progression. JAMA Ophthalmol. 2024. PMID: 38696186. doi:10.1001/jamaophthalmol.2024.0906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。